DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the ...

Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...

For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is ...

Shares of DexCom Inc. DXCM shed 3.06% to $76.00 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.30% to 6,532.04 and the ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

Shares of DexCom Inc. DXCM rallied 3.10% to $60.23 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.98% to 6,602.99 and the ...

The average one-year price target for DexCom (BIT:1DXCM) has been revised to €77.53 / share. This is a decrease of 12.39% from the prior estimate of €88.50 dated November 9, 2025. The price target is ...